Caribou Biosciences Price Targets Raised to $9 After Q3 EPS Beat
CRBU shares rose 0.6% to $1.59 on Tuesday, with trading volume climbing 13% to 1.04 million shares versus the 918,003 daily average. Analysts at Citigroup and HC Wainwright raised target prices to $8.00 and $9.00, while Q3 EPS of -$0.30 beat estimates by $0.06 on $2.2 million revenue.
1. Trading Activity and Volume Surge
Shares of Caribou Biosciences advanced by 0.6% during Tuesday’s session, driven by a surge in trading volume. Approximately 1,035,077 shares changed hands, representing a 13% increase over the three-month average of 918,003 shares. The company’s 50-day moving average stands at 1.81 and its 200-day moving average at 1.96, reflecting recent volatility in the name. With a market capitalization of $148.62 million, a P/E ratio of -0.94 and a beta of 2.61, Caribou continues to attract attention from momentum-focused investors.
2. Analyst Rating Revisions
Over the past month, Caribou Biosciences has seen multiple target-price upgrades and rating changes. Citigroup raised its target from 5.00 to 8.00 and maintained a Buy rating, while Truist Financial set a 7.00 target and HC Wainwright increased its projection from 3.00 to 9.00, also with a Buy recommendation. Weiss Ratings reaffirmed a Sell (D-) stance. Of the three analysts reporting, two rate the shares as Buy and one as Sell, yielding an average consensus of Hold and an average target of 8.00.
3. Recent Financial Results
In its latest quarterly filing, Caribou Biosciences posted an adjusted loss per share of 0.30, outperforming consensus by 0.06. Revenue reached 2.20 million, surpassing estimates of 1.94 million. Despite these beats, the company recorded a negative net margin of 1,690.45% and a return on equity of -69.85%. Looking ahead, analysts forecast a full-year loss per share of 1.64, underscoring the need for continued operational leverage and clinical progress to drive profitability.
4. Institutional Ownership Trends
Institutional investors control a commanding 77.51% of Caribou’s outstanding shares. During the third quarter, Vanguard Group increased its position by 3.4% to 4.23 million shares (valued at 9.85 million), Millennium Management added 1.67 million shares (up 107.4%) for a holding of 3.22 million, and Aberdeen Group lifted its stake by 54.7% to 1.39 million shares (3.24 million value). Bank of America grew its stake by 32.8% to 1.07 million shares (2.50 million value), while AQR Capital Management expanded its position by 741.6% to 525,878 shares (480,000 value).